Navigation Links
ACEA Biosciences Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery
Date:11/29/2018

ACEA Biosciences, now a part of Agilent Technologies, is excited to collaborate with the new NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable and low-cost production of high-quality living therapeutic cells. The center, launched in 2017 with a $20 million investment from the National Science Foundation, aims to revolutionize the treatment of cancer, heart disease, autoimmune diseases and other disorders by enabling broad use of potentially curative therapies that utilize living cells – such as immune cells and stem cells – as “drugs.”

“ACEA Biosciences is committed to improving processes related to cell therapy discovery and innovation,” said Dr. Yama Abassi, Vice President at ACEA Biosciences. “We are eager to work with the Krish Roy lab at Georgia Tech University to develop potency assays for CAR-T cells, which is a promising form of immunotherapy. The automated, high throughput xCELLigence Real Time Cell Analysis MP system will be used to measure the kinetics of tumor cell killing by the CAR-T cells, allowing for robust screening of CAR-T cell therapies. We are thrilled to provide an efficient platform to help advance manufacturing processes for these life-saving cell therapies.”

To facilitate the widespread application of these cutting-edge emerging treatments, CMaT will develop robust and scalable technologies, innovative analytical tools, and engineering systems that will enable industry and clinical facilities to reproducibly manufacture efficient, safe and affordable cell-therapy products. The center will also develop improved models for a robust supply chain, storage and distribution system for these therapeutic cell products.

In addition to the consistent manufacture of cell-based therapies, the public-private CMaT initiative will also help develop a skilled, diverse and inclusive bio-manufacturing workforce through extensive education and training activities at the K-12, technical college, undergraduate, graduate and postdoctoral levels.

“We are pleased to welcome ACEA Biosciences to this new initiative,” said Krishnendu Roy, director of CMaT and the Robert A. Milton chair professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. “The center will develop the technologies needed to use living cells in standardized therapies by clinicians to serve large numbers of patients worldwide. We are very excited about what this will mean to the world.”

Beyond Georgia Tech, the center includes major university partners – the University of Georgia, the University of Wisconsin-Madison and the University of Puerto Rico, Mayaguez Campus – as well as affiliate partners such as the University of Pennsylvania, Emory University, the Gladstone Institutes and Michigan Technological University. Additional international academic partners, as well as industry and the U.S. national laboratories, will also be critical collaborators in the effort.

About xCELLigence® Real Time Cell Analysis (RTCA)
ACEA Biosciences’ xCELLigence RTCA instruments are being used in both academia and industry for life science applications ranging from cancer immunotherapy, bacterial biofilms, vaccine development and cardiotoxicity testing. With the xCELLigence technology, scientists can non-invasively monitor the behavior of cells by quantifying cell proliferation, morphology change, and attachment quality in a label-free, real-time manner.

About ACEA Biosciences
ACEA Biosciences, a part of Agilent Technologies, is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® aQuanteon flow cytometers are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,500 instruments have been placed globally, and have been used in more than 1,800 peer-reviewed publications.

For more information visit: http://www.aceabio.com.
Follow on LinkedIn, Twitter, and Facebook

For further information please contact:
ACEA Biosciences, Inc.
Dr. Jeff Xue
Phone: 858-299-8023
email: jxue(at)aceabio(dot)com

Read the full story at https://www.prweb.com/releases/acea_biosciences_joins_cell_manufacturing_research_initiative_to_further_advance_cell_therapy_discovery/prweb15954443.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... January 09, 2019 , ... Dr. Beanlands is the Vered Chair and ... Canada. He is also Director of its National Cardiac PET Centre, and Professor ... of Radiology, and in the Department of Cellular and Molecular medicine. , He is ...
(Date:1/8/2019)... ... ... Join industry experts Julie Peacock, Client Services at Comprehend and Heather Davis, Independent Consultant ... at 1pm EST. , This webinar will dive into best practices for the ... also present a case study of a leading pharmaceutical company that faced multiple challenges ...
(Date:1/7/2019)... ... January 07, 2019 , ... Concerto HealthAI, a ... precision health in oncology and other key therapeutic areas, and its Chief Executive ... entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, at ...
Breaking Biology News(10 mins):
(Date:2/14/2019)... ... February 14, 2019 , ... ... leak testing systems for the pharmaceutical, biotechnology and food industries, formally announced today ... Brian Mulhall has been named Chief Executive Officer and will oversee ...
(Date:2/2/2019)... DALLAS (PRWEB) , ... January 31, 2019 , ... ... decades of research and clinical use of perinatal tissue by applied stem cell ... research and development team. Signature Cord is a flowable umbilical cord tissue allograft ...
(Date:1/30/2019)... ... January 29, 2019 , ... ... today announced the dosing of the first patient in a phase 1/2 clinical ... serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... ... January 30, 2019 , ... In ... tasting 5StarWines to promote and give recognition to producers whose work focuses entirely ... selection takes place in Verona, Italy, contemporaneously to the 5StarWines blind tasting organized ...
Breaking Biology Technology: